Bart L Haagmans Selected Research

Interferons

1/2014	Presence of anti-interferon antibodies is not associated with non-response to pegylated interferon treatment in chronic hepatitis B.
1/2013	Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection.
1/2012	Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3.
2/2011	Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms.
2/2010	Nonresponder patients with hepatitis C virus genotype 2/3 infection: a question of low systemic interferon concentrations?
1/2009	Unraveling the complexities of the interferon response during SARS-CoV infection.
1/2007	Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B.
10/2006	Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection.
9/2006	Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response.
6/2003	A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bart L Haagmans Research Topics

Disease

53	Infections 05/2024 - 01/2002
28	COVID-19 05/2024 - 01/2020
12	Virus Diseases (Viral Diseases) 03/2024 - 11/2003
9	Chronic Hepatitis C 01/2014 - 06/2003
7	Coronavirus Infections 01/2023 - 10/2014
4	Chronic Hepatitis B 01/2014 - 09/2006
3	Inflammation (Inflammations) 12/2023 - 02/2010
2	Pneumonia (Pneumonitis) 12/2022 - 01/2021
2	Respiratory Tract Infections (Respiratory Tract Infection) 01/2022 - 06/2017
2	Communicable Diseases (Infectious Diseases) 01/2021 - 01/2020
2	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2020 - 08/2007
2	Hepatitis 11/2014 - 08/2003
1	Thrombocytopenia (Thrombopenia) 12/2023
1	Leprosy (Hansen's Disease) 12/2023
1	Vaccinia 01/2023
1	Smallpox (Variola) 01/2023
1	Disease Progression 12/2022
1	Zoonoses 06/2022
1	Hyperplasia 01/2022
1	Critical Illness (Critically Ill) 01/2022
1	Asymptomatic Infections 12/2021
1	Weight Loss (Weight Reduction) 01/2021
1	Respiratory Tract Diseases (Respiratory Tract Disease) 01/2021
1	Emerging Communicable Diseases (Emerging Infectious Diseases) 05/2020
1	Cytokine Release Syndrome 01/2020
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2018
1	Acute Disease 01/2018
1	Viremia 05/2016
1	Multiple Sclerosis 02/2016

Drug/Important Bio-Agent (IBA)

22	VaccinesIBA 05/2024 - 04/2011
15	Neutralizing AntibodiesIBA 05/2024 - 03/2006
14	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2002
14	AntibodiesIBA 01/2023 - 03/2013
13	Antiviral Agents (Antivirals)IBA 12/2023 - 11/2003
10	Monoclonal AntibodiesIBA 03/2024 - 06/2004
10	InterferonsIBA 01/2014 - 06/2003
7	Ribavirin (Virazole)FDA LinkGeneric 01/2013 - 06/2003
5	RNA (Ribonucleic Acid)IBA 01/2019 - 02/2011
4	Viral RNAIBA 11/2021 - 08/2013
3	Immunoglobulin G (IgG)IBA 01/2022 - 04/2004
3	LipopeptidesIBA 01/2022 - 11/2020
3	AntigensIBA 01/2021 - 03/2004
3	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 01/2018 - 08/2013
3	Interferon-alpha (Interferon Alfa)IBA 01/2007 - 06/2003
2	N-(2-cyanoethylene)urea (BA 1)IBA 05/2024 - 12/2022
2	Messenger RNA (mRNA)IBA 12/2023 - 01/2018
2	BNT162 VaccineIBA 12/2023 - 01/2021
2	remdesivirIBA 12/2023 - 07/2022
2	EpitopesIBA 01/2022 - 01/2020
2	Viral AntigensIBA 01/2022 - 03/2019
2	Viral ProteinsIBA 01/2021 - 08/2013
2	Staphylococcal Protein A (Protein A)IBA 05/2020 - 10/2014
2	ChemokinesIBA 01/2013 - 08/2007
2	CytokinesIBA 01/2013 - 08/2007
2	Hepatitis B e AntigensIBA 01/2007 - 09/2006
1	Acyclovir (Aciclovir)FDA LinkGeneric 01/2024
1	Cidofovir (Vistide)FDA Link 01/2024
1	Ad26COVS1IBA 12/2023
1	Platelet Factor 4IBA 12/2023
1	COVID-19 VaccinesIBA 12/2023
1	AutoantibodiesIBA 12/2023
1	ChAdOx1 nCoV-19IBA 12/2023
1	2019-nCoV Vaccine mRNA-1273IBA 12/2023
1	Clofazimine (Lamprene)FDA Link 12/2023
1	Therapeutic UsesIBA 12/2023
1	NucleoproteinsIBA 01/2023
1	Aluminum Hydroxide (Algeldrate)FDA Link 01/2023
1	Smallpox Vaccine (Vaccine, Smallpox)FDA Link 01/2023
1	FucoseIBA 01/2023
1	MucinsIBA 01/2023
1	N-Acetylneuraminic Acid (Sialic Acid)IBA 01/2023
1	smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordicIBA 01/2023
1	Polysaccharides (Glycans)IBA 01/2023
1	Synthetic Vaccines (Recombinant Vaccines)IBA 01/2023
1	molnupiravirIBA 07/2022
1	Immune Sera (Antisera)IBA 01/2022
1	NanovaccinesIBA 01/2021
1	Complement System Proteins (Complement)IBA 01/2021
1	Protein Subunit VaccinesIBA 05/2020
1	Subunit VaccinesIBA 05/2020
1	Interleukin-6 (Interleukin 6)IBA 01/2020
1	Broadly Neutralizing AntibodiesIBA 01/2020
1	Interleukin-10 (Interleukin 10)IBA 01/2020
1	Inactivated VaccinesIBA 01/2020
1	LigandsIBA 01/2019
1	Neuraminidase (Sialidase)IBA 01/2019
1	Cell Surface ReceptorsIBA 01/2018
1	GoldIBA 01/2018
1	Edetic Acid (EDTA)FDA Link 05/2016
1	AutoantigensIBA 02/2016
1	Cardiac GlycosidesIBA 04/2015
1	src-Family KinasesIBA 04/2015
1	bufalinIBA 04/2015
1	Ouabain (G Strophanthin)IBA 04/2015

Therapy/Procedure

12	Therapeutics 01/2022 - 06/2003
2	Intranasal Administration 01/2021 - 11/2020
1	Drug Therapy (Chemotherapy) 01/2024
1	Artificial Respiration (Mechanical Ventilation) 01/2020
1	Length of Stay 01/2017
1	Hand Hygiene 01/2017